

Bibliography

1. [Baum A, Fulton BO, Wloga E, et al. *Science*. 2020;369\(6506\):1014-1018.](#) An investigation demonstrating that a combination of monoclonal antibodies to the SARS-CoV-2 spike protein prevents the rapid mutational escape seen with individual antibodies.
2. [Baum A, Ajithdoss D, Copin R, et al. *Science*. 2020;370\(6520\):1110-1115.](#) A preclinical study showing that casirivimab and imdevimab prevent and treat SARS-COV-2 infection in rhesus macaques and hamsters.
3. [Copin R, Baum A, Wloga E, et al. *bioRxiv*. 2021.](#) In vitro and in vivo preclinical studies that predict using casirivimab with imdevimab protects against emergence of viral escape in humans.
4. [COVID-19 Treatment Guidelines Panel. *Coronavirus Disease 2019 \(COVID-19\) Treatment Guidelines*. National Institutes of Health website. \[www.covid19treatmentguidelines.nih.gov\]\(http://www.covid19treatmentguidelines.nih.gov\).](#) NIH treatment guidelines for COVID-19.
5. [Hansen J, Baum A, Pascal K, et al. *Science*. 2020;369\(6506\):1010-1014.](#) Studies in humanized mice and convalescent humans yield a pair of neutralizing antibodies against the SARS-CoV-2 spike protein.
6. [Infectious Disease Society of America \(IDSA\). IDSA home page. \[www.idsociety.org\]\(http://www.idsociety.org\).](#) IDSA resource with expertly curated, timely information on COVID-19 for the frontline healthcare community.
7. [Weinreich DM, Sivapalasingam S, Norton T, et al. *N Engl J Med*. 2021;384\(3\):238-251.](#) Results of an interim analysis of an ongoing, double-blind phase 1-3 trial investigating safety and efficacy of casirivimab and imdevimab in nonhospitalized patients with COVID-19.
8. [Weinreich DM, Sivapalasingam S, Norton T, et al. *medRxiv*. 2021.](#) Phase 3 clinical outcomes of casirivimab and imdevimab, administered together, from an ongoing trial in outpatients with COVID-19.